Showing results (21-30 of 26) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
ESMO Open|March 5, 2026
Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in ER-positive, HER2-negative advanced breast cancer: an indirect treatment comparison of three phase III trialsK Jhaveri, F C Bidard, K Kalinsky, et al.ESMO Open|June 14, 2025
Characteristics of real-world NATALEE- and monarchE-eligible populations with HR+/HER2- early breast cancer: a United States Electronic Health Records database analysisP Tarantino, H S Rugo, G Curigliano, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 25, 2025
Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone-receptor-positive HER2-negative breast cancer: final overall survival analysis of the phase 3 TROPION-Breast01 studyB Pistilli, K Jhaveri, S-A Im, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 19, 2020
Characterization of on-target adverse events caused by TRK inhibitor therapyD Liu, J Flory, A Lin, et al.Current Oncology (Toronto, Ont.)|June 7, 2012
Eastern Canadian colorectal cancer consensus conference: application of new modalities of staging and treatment of gastrointestinal cancersT Di Valentin, Y Alam, A Ali Alsharm, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 19, 2023
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trialK Jhaveri, L D Eli, H Wildiers, et al.Pageof 3